Impax, AstraZeneca Get Win In Generic Zomig Patent Case

Law360, New York (April 3, 2017, 5:32 PM EDT) -- A Delaware federal judge has given a victory to Impax Laboratories Inc. and AstraZeneca AB in their patent infringement suit over Lannett Holdings Inc.'s planned generic version of the migraine medication Zomig, upholding the validity of two patents Lannett conceded it infringed.

The Wednesday decision by U.S. District Judge Richard Andrews, issued following a bench trial held in September, effectively bars Lannett from launching its version of Zomig.

AstraZeneca owns the two patents on a nasal spray formulation of the drug zolmitriptan and licensed them to Impax for use in Zomig. The patents expire in November 2020, but have exclusivity for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!